Evidence map›Paper›PMID 38853451›Full record

ArticleClinical and experimental dental research2024

Diagnostic value of aMMP-8 and azurocidin in peri-implant sulcular fluid as biomarkers of peri-implant health or disease.

Vithleem Xanthopoulou, Ismo T Räisänen, Timo Sorsa, Dimitrios Tortopidis, Dimitra Sakellari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental dental research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vithleem XanthopoulouDepartment of Preventive Dentistry, Periodontology and Implant Biology, Dental School, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0000-0003-3136-706X
Ismo T RäisänenDepartment of Oral and Maxillofacial Diseases, Head and Neck Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0001-5821-5299
Timo SorsaDepartment of Oral and Maxillofacial Diseases, Head and Neck Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Dimitrios TortopidisDepartment of Prosthodontics, Dental School, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0000-0001-8801-9184
Dimitra SakellariDepartment of Preventive Dentistry, Periodontology and Implant Biology, Dental School, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Funding

Finnish Dental Society Apollonia, Finland N/AHelsinki and Uusimaa Hospital District (HUS) TYH2020337Helsinki and Uusimaa Hospital District (HUS) TYH2022225Helsinki and Uusimaa Hospital District (HUS) Y1Helsinki and Uusimaa Hospital District (HUS) Y1014SULE1Helsinki and Uusimaa Hospital District (HUS) Y2519SU010karolisnka institute N/A
6 · The paper itself

Abstract

objectiveThe objective of this study was to investigate the effectiveness of testing for active matrix metalloproteinase-8 (aMMP-8) by a quantitative point-of-care (PoC), chairside lateral flow immunotest and azurocidin, in the peri-implant sulcular fluid (PISF), as biomarkers for the presence or absence of peri-implant diseases.

backgroundCurrent research indicates that proinflammatory cytokines and extracellular matrix-degrading enzymes may be of value to diagnose and predict peri-implant disease initiation and progression, but more data are needed.

methodsEighty patients with implants were recruited. PISF samples were collected and quantitatively analyzed for aMMP-8 (chairside) and azurocidin with ELISA. Radiographic assessments and clinical indices (probing depth, probing attachment level, bleeding on probing, and plaque) were recorded after sampling. Kruskal-Wallis test and pairwise post hoc Dunn-Bonferroni test were used to relate aMMP-8 levels and azurocidin levels to clinical parameters. The diagnostic ability of aMMP-8 (ng/mL) and azurocidin was analyzed by receiver operator curve analysis. Area under the curve (AUC) was calculated and the Spearman's rho, and the coefficient of determination (R

resultsStatistically significant differences were observed for aMMP-8 levels but not for azurocidin between healthy implants, implants with mucositis, and those with peri-implantitis (13.65 ± 7.18, 32.33 ± 21.20, and 73.07 ± 43.93 ng/mL, respectively), (Kruskall-Wallis test p < .05). The aMMP-8 test with a threshold of 20 ng/mL has a sensitivity of 71.7% and a specificity of 77.8% to identify peri-implantitis and healthy implants, respectively. AUC was found to be 0.814, and the accuracy of the method reaches 73.8%. Above a cutoff value of 33.7 ng/mL of aMMP-8, the accuracy of the test to detect peri-implantitis reaches 77.5% in relation to 62.5% of BoP from the same site.

conclusionTaken collectively, present data indicate that the aMMP-8 PoC lateral flow immunotest can be a beneficial, adjunctive diagnostic quantitative tool for real-time screening for peri-implant diseases.

Indexed as

BiomarkersDental ImplantsGingival Crevicular FluidMatrix Metalloproteinase 8Peri-ImplantitisAdultAgedAntimicrobial Cationic PeptidesBlood ProteinsEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedPeriodontal IndexROC CurveAntimicrobial Cationic PeptidesAZU1 protein, humanBiomarkersBlood ProteinsDental ImplantsMatrix Metalloproteinase 8MMP8 protein, humanaMMP‐8azurocidinperi‐implant diseaseperi‐implant health

Identifiers

PMID38853451
PMCPMC11163026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.